Life AI Net
Home
Archive
Calculators
Directory
Newsletter
Login
English
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Home
Archive
Calculators
Directory
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Login
Home
Archive
Calculators
Directory
More
Live
FierceBiotech
Affibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection
FierceBiotech
Insulet debuts latest enhancements to popular Omnipod insulin delivery system
PharmaVoice
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak
Promega Blog
Measuring What Matters in Metabolic Research: A Bioluminescent Toolkit
BioWorld
NME Digest: Q1 2026
FierceBiotech
Chutes & Ladders—AstraZeneca adds FDA cell and gene veteran
BioWorld
New York University identifies new analogues of mannose-6-phosphate
BioWorld
Avelos Therapeutics synthesizes new PARG inhibitors
BioWorld
Simcere Zaiming Pharmaceutical discovers new MAPK inhibitors
Labiotech
Eight oncology deals in 2026 spotlight where industry leaders are betting big
Endpoints News
Fulcrum lays off majority of staff; Seres extends runway into 2027
PharmaVoice
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
FierceBiotech
Affibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection
FierceBiotech
Insulet debuts latest enhancements to popular Omnipod insulin delivery system
PharmaVoice
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak
Promega Blog
Measuring What Matters in Metabolic Research: A Bioluminescent Toolkit
BioWorld
NME Digest: Q1 2026
FierceBiotech
Chutes & Ladders—AstraZeneca adds FDA cell and gene veteran
BioWorld
New York University identifies new analogues of mannose-6-phosphate
BioWorld
Avelos Therapeutics synthesizes new PARG inhibitors
BioWorld
Simcere Zaiming Pharmaceutical discovers new MAPK inhibitors
Labiotech
Eight oncology deals in 2026 spotlight where industry leaders are betting big
Endpoints News
Fulcrum lays off majority of staff; Seres extends runway into 2027
PharmaVoice
GSK, Takeda and others notch key clinical wins in tough-to-treat diseases
Archive
This story is not available in the archive.